Interview with Lisa Hornick, OD, FAAO, from Stanford Ranch Optometry. Optometry Diva’s Dr. Lisa Hornick brings us her fresh clinical perspective on helpful dry eye therapies utilizing improved drug delivery systems, as well as discussing her tips for dry eye treatment success.
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of proprietary NCE development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
